tiprankstipranks
Trending News
More News >
Alcidion Group Limited (AU:ALC)
ASX:ALC
Australian Market

Alcidion Group Limited (ALC) AI Stock Analysis

Compare
17 Followers

Top Page

AU

Alcidion Group Limited

(Sydney:ALC)

Rating:55Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
Alcidion Group Limited has a moderate overall stock score driven by strong technical indicators indicating positive market momentum. However, significant financial performance issues, including persistent losses and negative cash flows, weigh heavily on the score. The lack of profitability and dividend yield further detracts from the valuation perspective.

Alcidion Group Limited (ALC) vs. iShares MSCI Australia ETF (EWA)

Alcidion Group Limited Business Overview & Revenue Model

Company DescriptionAlcidion Group Limited, together with its subsidiaries, engages in the development and licensing of healthcare software products in Australia, New Zealand, and the United Kingdom. The company offers Miya Precision, a consolidated fast healthcare interoperability resource (FHIR) based platform to deliver smart healthcare; Smartpage, a smartphone and web-based system for hospital communication and task management to address the requirements of clinical and non-clinical users; Patientrack, a real-time patient monitoring and risk screening solution; Silverlink, a patient administration system; and ExtraMed, a clinical and patient flow management software. It also provides product implementation, product support and maintenance, systems integration, and data analysis services. The company was formerly known as Alcidion Corporation Pty Ltd and changed its name to Alcidion Group Limited in December 2015. Alcidion Group Limited was founded in 2000 and is headquartered in South Yarra, Australia.
How the Company Makes MoneyAlcidion Group Limited generates revenue primarily through the sale and licensing of its software solutions to healthcare providers such as hospitals and health systems. The company's key revenue streams include subscription fees for its software-as-a-service (SaaS) offerings, implementation and integration services, and ongoing support and maintenance contracts. Additionally, Alcidion forms strategic partnerships with other healthcare technology providers and institutions to expand its market reach and enhance its product offerings, which can also contribute to its revenue growth.

Alcidion Group Limited Financial Statement Overview

Summary
Alcidion Group Limited faces challenges with profitability and cash generation, despite a strong equity base and low leverage. The company needs to improve operational efficiency and stabilize revenue growth to enhance financial stability. Continued losses and negative cash flows are areas of concern.
Income Statement
45
Neutral
The company has shown volatility in its revenue with a decrease from the previous year. Gross profit margin is strong at approximately 86.1%, but net profit margin is deeply negative due to substantial losses. EBIT and EBITDA margins are also negative, indicating operational inefficiencies and high operating costs.
Balance Sheet
60
Neutral
The company maintains a strong equity position with an equity ratio of approximately 75.9%. However, consistent losses have led to a negative return on equity. The debt-to-equity ratio is low at 0.02, indicating minimal leverage which poses less financial risk.
Cash Flow
40
Negative
Cash flow from operations is negative, and free cash flow has decreased from the previous year, indicating challenges in generating cash from core activities. The free cash flow to net income ratio is negative, reflecting operational difficulties.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue35.64M37.06M40.40M34.35M25.88M18.55M
Gross Profit30.55M31.92M1.25M3.29M3.52M401.23K
EBITDA-3.50M-4.50M-1.43M-1.58M-474.00K-3.77M
Net Income-4.97M-8.42M-3.62M-4.41M-2.24M-3.08M
Balance Sheet
Total Assets116.04M114.46M120.68M128.35M58.38M39.43M
Cash, Cash Equivalents and Short-Term Investments7.91M11.80M14.64M17.34M25.03M15.95M
Total Debt2.08M1.70M2.15M2.48M181.00K315.85K
Total Liabilities24.89M27.52M30.52M34.40M13.16M9.70M
Stockholders Equity91.16M86.94M90.17M93.95M45.22M29.74M
Cash Flow
Free Cash Flow153.00K-7.18M-285.00K685.00K1.23M-2.14M
Operating Cash Flow171.00K-7.13M169.00K996.00K1.54M-2.02M
Investing Cash Flow-18.00K-53.00K-3.14M-59.74M-9.84M-362.04K
Financing Cash Flow-688.00K4.34M-616.00K51.33M17.23M15.16M

Alcidion Group Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.10
Price Trends
50DMA
0.09
Positive
100DMA
0.09
Positive
200DMA
0.07
Positive
Market Momentum
MACD
<0.01
Negative
RSI
54.46
Neutral
STOCH
21.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ALC, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.09, and above the 200-day MA of 0.07, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.46 is Neutral, neither overbought nor oversold. The STOCH value of 21.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ALC.

Alcidion Group Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUALC
55
Neutral
AU$134.30M-5.63%-11.96%7.50%
51
Neutral
$7.50B0.32-61.87%2.27%17.10%1.59%
$121.92M
$53.06M-9.88%
AUPCK
55
Neutral
AU$81.05M-457.46%21.93%10.34%
AUSHG
54
Neutral
AU$113.13M
AUBMT
48
Neutral
AU$69.73M-11.80%14.56%13.36%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:ALC
Alcidion Group Limited
0.10
0.05
100.00%
ONVVF
Oneview Healthcare Chess Depository Interests repr 1
0.16
0.02
14.29%
TDMMF
Mach7 Technologies Ltd.
0.24
-0.12
-33.33%
AU:BMT
Beamtree Holdings Ltd
0.24
0.03
14.29%
AU:SHG
Singular Health Group Ltd
0.38
0.29
322.22%
AU:PCK
PainChek Ltd
0.04
0.01
33.33%

Alcidion Group Limited Corporate Events

Alcidion Group Boosts FY25 Financial Guidance Amid Strong Performance
Jun 22, 2025

Alcidion Group Limited has upgraded its financial guidance for the fiscal year ending June 2025, expecting EBITDA to exceed $4.5 million, up from the previous forecast of over $3.0 million. This improvement is attributed to smaller contract upgrades, extensions, diligent cost management, and favorable foreign exchange movements. The company’s Miya platform continues to gain traction, leading to increased customer engagement and new opportunities, reinforcing Alcidion’s long-term value proposition and ability to address critical challenges in global hospital systems.

The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.

Alcidion Group Limited Announces Cessation of Performance Rights
Jun 3, 2025

Alcidion Group Limited announced the cessation of 206,458 performance rights due to the lapse of conditional rights that were not satisfied by the specified date. This development may impact the company’s capital structure and could have implications for stakeholders as it reflects on the company’s performance metrics and strategic objectives.

The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.

Alcidion Announces Board Change with Director Departure
May 29, 2025

Alcidion Group Limited has announced a change in its board of directors, with Victoria Weekes ceasing to be a director as of May 30, 2025. This update, in compliance with ASX Listing Rule 3.19A.3, is part of the company’s ongoing corporate governance and may impact its strategic direction as it continues to expand its healthcare technology services globally.

The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.

Alcidion Group to Release Q3 FY25 Results and Host Investor Webcast
Apr 16, 2025

Alcidion Group Limited announced the release of its Appendix 4C and Quarterly Cash Flow Report for Q3 FY25, scheduled for April 22, 2025. A live webcast will be hosted by the company’s CEO and CFO to discuss the quarter’s operational and commercial highlights, offering stakeholders insights into the company’s performance and strategic direction.

Alcidion Group Appoints New Director to Strengthen Leadership
Apr 14, 2025

Alcidion Group Limited has announced the appointment of Andrew Way as a director, effective from April 15, 2025, as per the ASX listing rule 3.19A.1. This appointment is part of Alcidion’s ongoing efforts to strengthen its leadership team, potentially impacting its strategic direction and market positioning in the healthcare technology sector.

Alcidion Appoints Professor Andrew Way AM as Non-Executive Director
Apr 14, 2025

Alcidion Group Limited has announced the appointment of Professor Andrew Way AM as a Non-Executive Director, succeeding Victoria Weekes who will step down mid-year. Professor Way brings extensive experience in healthcare management and IT, aligning with Alcidion’s mission to support the healthcare industry. His appointment is part of Alcidion’s strategic plan to scale the company and expand its customer base, leveraging his expertise in quality patient care and healthcare systems.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 24, 2025